BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/1/2014 10:54:00 AM | Browse: 995 | Download: 824
Publication Name World Journal of Dermatology
Manuscript ID 4577
Country Japan
Received
2013-07-08 09:53
Peer-Review Started
2013-07-08 14:17
To Make the First Decision
2013-07-26 18:39
Return for Revision
2013-08-01 11:14
Revised
2013-08-14 10:23
Second Decision
2013-09-03 14:29
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-09-04 07:37
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2013-09-29 14:12
Publish the Manuscript Online
2013-10-31 15:06
ISSN 2218-6190 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Dermatology
Manuscript Type Minireviews
Article Title Potential biomarkers for malignant melanoma
Manuscript Source Invited Manuscript
All Author List Ye-Nan Wang, Yuki Yamamoto and Fukumi Furukawa
Funding Agency and Grant Number
Corresponding Author Ye-Nan Wang, MD, Department of Dermatology, Wakayama Medical University, 811-1, Kimiidera, Wakayama City, Wakayama 641-0012, Japan. wangyenan1112@live.cn
Key Words Melanoma; Prognosis; Survival; Biological marker; Immunohistochemistry
Core Tip Melanoma is one of the most common cancers and its high metastatic potential has a large impact on the number of melanoma deaths. Emerging molecular knowledge may lead to further identification of clinically relevant biomarkers, such as S100B, MIA, TA-90IC, 5-S-CD, SPARC, CSPG4, HSP105, IMP3, KIF2A, miR-221, YKL-40, some cancer stem cells (CD133, Nestin, CD166, CD20, CD271) and some monoclonal antibodies (KBA62, PNL2), for malignant melanoma detection, risk stratification and prediction/prognosis. However, all current markers have some shortcomings and thus we expect there will be more novel melanoma biomarkers discovered as supplementary diagnostic criteria in the near future.
Publish Date 2013-10-31 15:06
Citation Wang YN, Yamamoto Y, Furukawa F. Potential biomarkers for malignant melanoma. World J Dermatol 2013; 2(4): 44-50
URL http://www.wjgnet.com/2218-6190/full/v2/i4/44.htm
DOI http://dx.doi.org/10.5314/wjd.v2.i4.44
Full Article (PDF) WJD-2-44.pdf
Manuscript File 4577-Review.docx
Answering Reviewers 4577-Answering reviewers.pdf
Copyright License Agreement 4577-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate 4577-Language certificate.pdf
Peer-review Report 4577-Peer review(s).pdf
Scientific Editor Work List 4577-Scientific editor work list.doc